Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACT Followed by Surgery vs Surgery in IB2/IIA2 Cervical Cancer
NCT02629718Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2015
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, cisplatin and carboplatin in Cervical Cancer (CC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Disease Free Survival at 2 years. Status: unknown.
02
Drugs
paclitaxelcisplatincarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02629718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629718.